Liofilchem® Tigecycline TGC Antimicrobial Susceptibility Discs, 15 µg

Standardized Discs for In Vitro Susceptibility Testing of Tigecycline-Responsive Pathogens

Liofilchem® Tigecycline (TGC) 15 µg Discs are designed for the qualitative in vitro determination of bacterial susceptibility to tigecycline, a broad-spectrum glycylcycline antibiotic. These paper discs, impregnated with 15 micrograms of tigecycline, are used in Kirby-Bauer disc diffusion assays on Mueller-Hinton agar, enabling clinicians and microbiologists to predict clinical efficacy of tigecycline against a range of Gram-positive and Gram-negative bacteria.

Tigecycline is particularly effective against multi-drug resistant organisms, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and extended-spectrum β-lactamase (ESBL)-producing Enterobacterales. These discs are manufactured according to EUCAST and CLSI guidelines, ensuring consistent and reliable zone diameter readings for susceptibility classification.

✅ Key Features & Benefits

• 15 µg of Tigecycline per Disc – Standardized for zone interpretation per CLSI/EUCAST breakpoints
• Ready-to-Use Format – Convenient, pre-dosed filter paper discs for easy application on agar plates
• High-Quality Cellulose Discs – Ensure even diffusion and uniform antimicrobial activity
• Reliable Detection of Resistance – Particularly suited for MDR pathogens including CRE, MRSA, and VRE
• Traceable Lot & Expiration Info – Ensures regulatory compliance and batch consistency
• Compliant with International Standards – Conforms to CLSI M100 and EUCAST performance criteria

⚙ Technical Specifications

🧫 Applications

• Antibiotic Susceptibility Testing (AST) via disc diffusion (Kirby-Bauer method)
• Routine testing in clinical microbiology labs for detection of tigecycline susceptibility
• Surveillance of MDR organisms in hospital and reference laboratories
• Research on tigecycline activity against emerging resistant strains
• Evaluation of empiric therapy options in nosocomial infections

🦠 Target Pathogens

• Staphylococcus aureus (including MRSA)
• Enterococcus faecalis / Enterococcus faecium (including VRE)
• Escherichia coli, Klebsiella pneumoniae, Enterobacter spp. (including ESBL producers)
• Acinetobacter baumannii
• Streptococcus agalactiae, Streptococcus pneumoniae
• Other Enterobacterales and non-fermenters

🧪 Usage Guidelines

1. Prepare a bacterial lawn on Mueller-Hinton agar according to CLSI/EUCAST protocols.
2. Place the TGC 15 µg disc on the agar surface using sterile forceps or a disc dispenser.
3. Incubate at 35 ± 2°C for 16–20 hours (24 hours for slower-growing organisms).
4. Measure the diameter of the inhibition zone in millimeters.
5. Interpret results using the most recent CLSI or EUCAST breakpoints.

⚠ Always refer to the latest standard guidelines and antibiogram charts for interpretation.

📦 Ordering Information

🧴 Storage and Handling

• Store at 2–8 °C in a sealed container with desiccant
• Do not freeze
• Bring to room temperature before opening to avoid condensation
• Use within stated expiry date
• Avoid exposure to humidity and light to preserve antimicrobial potency

The Liofilchem® Tigecycline TGC 15 µg Antimicrobial Susceptibility Discs are a vital tool for clinical and research laboratories involved in the detection of tigecycline susceptibility, especially in multidrug-resistant organisms. Manufactured to strict international standards and offering reliable, reproducible results, these discs support informed antimicrobial stewardship and effective infectious disease management.